TouchREVIEWS in endocrinology最新文献_第3页

Erratum to Correct Informed Patient Consent Statement. 更正患者知情同意声明的勘误。

TouchREVIEWS in endocrinology Pub Date : 2024-04-01 Epub Date: 2023-12-07 DOI: 10.17925/EE.2024.20.1.2

Hiya Boro, Harish Sharma, Deepak Mittal, Mohit Pareek, Shilpa Chugh, Mohar Singh Jakhar, Neeraj Nagar, Lovekesh Bhatia, Sanjay Saini, Vashishth Joshi, Sahil Vaid, Velmurugan Mannar, Lakshmi Nagendra, Mazhar Dalv, Vikash Bundela

引用次数: 0

The Placental Role in Gestational Diabetes Mellitus: A Molecular Perspective. 胎盘在妊娠糖尿病中的作用：分子视角。

TouchREVIEWS in endocrinology Pub Date : 2024-04-01 Epub Date: 2024-03-14 DOI: 10.17925/EE.2024.20.1.5

María José Calvo, Heliana Parra, Raquel Santeliz, Jordan Bautista, Eliana Luzardo, Nelson Villasmil, María Sofía Martínez, Maricamen Chacín, Clímaco Cano, Ana Checa-Ros, Luis D'Marco, Valmore Bermúdez, Juan Bautista De Sanctis

{"title":"The Placental Role in Gestational Diabetes Mellitus: A Molecular Perspective.","authors":"María José Calvo, Heliana Parra, Raquel Santeliz, Jordan Bautista, Eliana Luzardo, Nelson Villasmil, María Sofía Martínez, Maricamen Chacín, Clímaco Cano, Ana Checa-Ros, Luis D'Marco, Valmore Bermúdez, Juan Bautista De Sanctis","doi":"10.17925/EE.2024.20.1.5","DOIUrl":"10.17925/EE.2024.20.1.5","url":null,"abstract":"During pregnancy, women undergo several metabolic changes to guarantee an adequate supply of glucose to the foetus. These metabolic modifications develop what is known as physiological insulin resistance. When this process is altered, however, gestational diabetes mellitus (GDM) occurs. GDM is a multifactorial disease, and genetic and environmental factors play a crucial role in its aetiopathogenesis. GDM has been linked to both macroscopic and molecular alterations in placental tissues that affect placental physiology. This review summarizes the role of the placenta in the development of GDM from a molecular perspective, including hormonal and pro-inflammatory changes. Inflammation and hormonal imbalance, the characteristics dominating the GDM microenvironment, are responsible for placental changes in size and vascularity, leading to dysregulation in maternal and foetal circulations and to complications in the newborn. In conclusion, since the hormonal mechanisms operating in GDM have not been fully elucidated, more research should be done to improve the quality of life of patients with GDM and their future children.","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":"20 1","pages":"10-18"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Panhypopituitarism in a Patient with Burkitt Lymphoma: A Diagnostic and Therapeutic Challenge. 伯基特淋巴瘤患者的泛垂体功能障碍：诊断和治疗的挑战。

TouchREVIEWS in endocrinology Pub Date : 2024-04-01 Epub Date: 2023-12-15 DOI: 10.17925/EE.2024.20.1.11

Augusto Dextre-Espinoza, Sofía Pilar Ildefonso-Najarro, Marcio José Concepción-Zavaleta, Juan Eduardo Quiroz-Aldave, Diana Carolina Deutz-Gómez Condori, Fiorella Beatriz Gonzales-Chiroque, Rodrigo Martín Rodríguez-Solis

{"title":"Panhypopituitarism in a Patient with Burkitt Lymphoma: A Diagnostic and Therapeutic Challenge.","authors":"Augusto Dextre-Espinoza, Sofía Pilar Ildefonso-Najarro, Marcio José Concepción-Zavaleta, Juan Eduardo Quiroz-Aldave, Diana Carolina Deutz-Gómez Condori, Fiorella Beatriz Gonzales-Chiroque, Rodrigo Martín Rodríguez-Solis","doi":"10.17925/EE.2024.20.1.11","DOIUrl":"10.17925/EE.2024.20.1.11","url":null,"abstract":"Pituitary infiltration by systemic lymphoma is an exceedingly rare occurrence. Given its high mortality rate, it is crucial to recognize its clinical, biochemical and radiological features in order to provide timely intervention. We present the case of a 26-year-old male with a history of human immunodeficiency virus (HIV) infection who presented to the hospital with severe anemia, persistent fever, weight loss and diarrhea over the previous 4 months. Physical examination revealed a compromised general condition, fever, pallor, hepatomegaly and lymphadenopathy. Cervical lymph node biopsy confirmed Burkitt lymphoma (BL). During hospitalization, the patient developed polyuria, polydipsia, hypernatremia, fluid-resistant hypotension and hypoglycaemia. Corticosteroid therapy was initiated due to suspected adrenal insufficiency, resulting in clinical improvement but exacerbation of polyuria and hypernatremia. Plasma and urinary osmolarity confirmed arginine vasopressin deficiency, and assessment of anterior pituitary reserve revealed hypopituitarism, necessitating hormonal replacement therapy. Sellar magnetic resonance imaging with contrast revealed pituitary infiltration. The patient subsequently developed septic shock and died. BL accounts for approximately 10% of the cases of pituitary infiltration associated with lymphoma. Clinical presentation is heterogeneous, with panhypopituitarism often serving as the initial manifestation. Sellar magnetic resonance imaging plays a pivotal role in the differential diagnosis. Management typically entails chemotherapy, immunotherapy, radiation and hormonal replacement therapy. This case report describes a patient with BL and HIV infection who developed panhypopituitarism due to pituitary infiltration, an exceedingly rare presentation considered a medical emergency.","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":"20 1","pages":"63-67"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Osilodrostat: A Novel Potent Inhibitor of 11-Beta-Hydroxylase for the Treatment of Cushing's Syndrome. 奥西洛司他用于治疗库欣综合征的新型强效 11-β-羟化酶抑制剂。

TouchREVIEWS in endocrinology Pub Date : 2024-04-01 Epub Date: 2023-12-11 DOI: 10.17925/EE.2024.20.1.8

Rosario Pivonello, Chiara Simeoli, Nicola Di Paola, Angelica Larocca, Erminio Massimo Crescenzo, Annamaria Colao

{"title":"Osilodrostat: A Novel Potent Inhibitor of 11-Beta-Hydroxylase for the Treatment of Cushing's Syndrome.","authors":"Rosario Pivonello, Chiara Simeoli, Nicola Di Paola, Angelica Larocca, Erminio Massimo Crescenzo, Annamaria Colao","doi":"10.17925/EE.2024.20.1.8","DOIUrl":"10.17925/EE.2024.20.1.8","url":null,"abstract":"Osilodrostat is a novel potent oral steroidogenesis inhibitor with a non-steroidal chemical structure, recently approved for the treatment of adult patients with endogenous Cushing's syndrome, and Cushing's disease not cured bytab pituitary surgery or in whom pituitary surgery is not an option. Osilodrostat has been evaluated in different multicentre phase II and III clinical studies, and has shown to have notable effects, such as significant reductions in cortisol secretion, associated with significant improvement in body weight, blood pressure, glucose metabolism, lipid profile, psychological status and quality of life. The favourable safety profile, combined with the relevant efficacy, could make osilodrostat suitable as medical treatment in several phases of the Cushing's syndrome treatment journey: before surgery, as preoperative treatment, or instead of surgery, in cases where surgery is not an option or refused, as first-line treatment; after surgery, in cases of persistent or recurrent disease, as second-line treatment; after second surgery or radiotherapy following pituitary surgery as bridging treatment waiting for the definitive disease control, as third-line treatment. Further real-world clinical experience data are needed to confirm the current knowledge.","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":"20 1","pages":"43-51"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bexagliflozin as an Adjunct Therapy to Diet and Exercise to Improve Glycaemic Control in Adults with Type 2 Diabetes. Bexagliflozin 作为饮食和运动的辅助疗法，改善 2 型糖尿病成人的血糖控制。

TouchREVIEWS in endocrinology Pub Date : 2024-04-01 Epub Date: 2023-12-19 DOI: 10.17925/EE.2024.20.1.6

Panagiotis Stachteas, Dimitrios Patoulias, Djordje S Popovic, Polyxeni Athanasiadou, Nikolaos Fragakis

{"title":"Bexagliflozin as an Adjunct Therapy to Diet and Exercise to Improve Glycaemic Control in Adults with Type 2 Diabetes.","authors":"Panagiotis Stachteas, Dimitrios Patoulias, Djordje S Popovic, Polyxeni Athanasiadou, Nikolaos Fragakis","doi":"10.17925/EE.2024.20.1.6","DOIUrl":"10.17925/EE.2024.20.1.6","url":null,"abstract":"Type 2 diabetes (T2D) is one of the leading causes of morbidity and mortality worldwide. Currently, over 10.5% of the adult population has been diagnosed with T2D, and almost 12% of total health expenditure is spent exclusively on T2D management globally. Sodium-glucose cotransporter-2 inhibitors are a relatively new class of oral antidiabetic agents that act by inhibiting renal sodium and glucose reabsorption. Except for their glucose-l owering effects, they have been associated with a more significant weight loss and blood pressure reduction and a lower risk of hypoglycaemia than other commonly prescribed antidiabetic drugs. On 20 January 2023, bexagliflozin became the fifth orally administered sodium-glucose transporter 2 inhibitor to be approved by the US Food and Drug Administration for the treatment of T2D as an adjunct therapy to diet and exercise in the USA after dapagliflozin, canagliflozin, empagliflozin and ertugliflozin. This review aims to discuss the current evidence on the efficacy and safety of bexagliflozin, which provides an important alternative treatment option for patients with T2D.","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":"20 1","pages":"19-24"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obesity and Oral Health: The Link Between Adipokines and Periodontitis. 肥胖与口腔健康：脂肪因子与牙周炎之间的联系

TouchREVIEWS in endocrinology Pub Date : 2024-04-01 Epub Date: 2024-01-25 DOI: 10.17925/EE.2024.20.1.7

Ana Checa-Ros, Wei-Chung Hsueh, Belén Merck, Henry González-Torres, Valmore Bermúdez, Luis D'Marco

{"title":"Obesity and Oral Health: The Link Between Adipokines and Periodontitis.","authors":"Ana Checa-Ros, Wei-Chung Hsueh, Belén Merck, Henry González-Torres, Valmore Bermúdez, Luis D'Marco","doi":"10.17925/EE.2024.20.1.7","DOIUrl":"10.17925/EE.2024.20.1.7","url":null,"abstract":"Periodontitis is a chronic inflammatory disease of the periodontium, or the supportive tissues around the tooth. This disease has been related to different risk factors, such as the presence of plaque and calculus, tobacco smoking, low socioeconomic status, and the immune state of the host. Importantly, the chronic inflammatory environment generated by periodontitis may lead to tooth loss and diverse systemic complications, such as cardiovascular disease, osteoarthritis and metabolic disease. Recent investigations have supported the role of obesity as a risk factor for periodontitis. Furthermore, studies have found obesity to compromise healing after periodontal therapy; however, the mechanisms underlying this association are not well understood. Proteins called 'adipokines' could be the factor linking obesity to periodontitis. Adipokines are bioactive molecules with hormonal properties and a structure similar to cytokines produced by the adipose tissue. Although adipokines have both pro-and anti-inflammatory effects, the shift towards pro-inflammatory actions occurs when the adipose tissue becomes pathological, as observe in the progression of conditions such as obesity or adiposopathy. This article reviews the role of adipokines in the pathophysiology and progression of periodontitis by focusing on their impact on inflammation and the molecular mechanisms through which adipokines contribute to the onset and development of periodontitis.","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":"20 1","pages":"25-31"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights into the Feasibility and Acceptability of a Mobile Insulin Titration Application in Clinical Practice and Its Effects on Diabetes Outcomes. 洞察移动胰岛素滴定应用程序在临床实践中的可行性和可接受性及其对糖尿病结果的影响。

TouchREVIEWS in endocrinology Pub Date : 2024-04-01 Epub Date: 2024-02-29 DOI: 10.17925/EE.2024.20.1.10

Jodi S Krall, Jason M Ng, Neha Mehrotra, Kristine Ruppert, Linda M Siminerio

{"title":"Insights into the Feasibility and Acceptability of a Mobile Insulin Titration Application in Clinical Practice and Its Effects on Diabetes Outcomes.","authors":"Jodi S Krall, Jason M Ng, Neha Mehrotra, Kristine Ruppert, Linda M Siminerio","doi":"10.17925/EE.2024.20.1.10","DOIUrl":"10.17925/EE.2024.20.1.10","url":null,"abstract":"Introduction: Insulin therapy is most effective if patients learn how to properly adjust insulin to achieve glycaemic targets. There is a need for methods and tools that can assist these processes in clinical practice. The purpose of this feasibility study was to evaluate an approach to support insulin dose adjustment in individual patients using a mobile titration application (app). Methods: A cohort of adults (N=36) with type 2 diabetes with suboptimal glycaemia who were starting basal insulin self-titration were trained by a diabetes care and education specialist to use a mobile titration app to guide adjusting insulin doses. Glycaemia, diabetes distress and patient and provider satisfaction were assessed during the first 3 months after initiating basal insulin titration using the mobile app. Results: Mean haemoglobin type A1c (HbA1c) was significantly reduced by an average of 2.1 ± 2.2% from baseline to 3 months (p<0.001). Diabetes distress significantly decreased from baseline to follow-up with scores going down (or improving) across all scales. Both patients and providers reported high levels of satisfaction and positive experiences. Conclusion: The model offers a promising solution to streamline insulin dosage adjustments to achieve specific clinical and self-management goals with high expectations for long-term benefits and warrants further investigation.","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":"20 1","pages":"52-57"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action. 代谢功能障碍相关性脂肪肝：全球行动的紧急呼吁》。

TouchREVIEWS in endocrinology Pub Date : 2024-04-01 Epub Date: 2023-11-08 DOI: 10.17925/EE.2023.20.1.1

Cornelius J Fernandez, Lakshmi Nagendra, Joseph M Pappachan

引用次数: 0

Fezolinetant: A Potential Treatment for Moderate to Severe Vasomotor Symptoms of Menopause. 非索内酯：治疗中度至重度更年期血管运动症状的潜在疗法。

TouchREVIEWS in endocrinology Pub Date : 2023-11-01 Epub Date: 2023-06-15 DOI: 10.17925/EE.2023.19.2.13

Barbara DePree

{"title":"Fezolinetant: A Potential Treatment for Moderate to Severe Vasomotor Symptoms of Menopause.","authors":"Barbara DePree","doi":"10.17925/EE.2023.19.2.13","DOIUrl":"10.17925/EE.2023.19.2.13","url":null,"abstract":"The most common symptom of menopause is vasomotor symptoms (VMS), which occur in more than 80% of postmenopausal women. Furthermore, VMS are the manifestation of menopause for which women most commonly seek treatment, namely, to address their impacted quality of life, including sleep, and work-and non-work-related productivity. VMS vary in frequency, intensity and duration. Hormone therapy (HT) has been our most effective treatment for VMS and has been approved for this indication by the United States Food and Drug Administration (FDA). Despite being a safe and effective treatment option, many patients and providers are hesitant to consider HT. Moreover, HT is contraindicated for some women. While many over-the-counter and non-HT options are available, we lack data on the efficacy and safety of most of these. This has left a void for women. Fezolinetant was recently approved by the FDA for the treatment of moderate-to-severe VMS. So far, clinical trials have shown positive results in terms of safety and efficacy. Fezolinetant is a non-hormonal, neurokinin 3 receptor antagonist that works in the hypothalamus at the thermoregulatory centre. Blocking the non-hormonal neurokinin 3 receptor antagonist modulates hot flashes and night sweats. As early as 4 weeks from initiating fezolinetant, women experienced a statistically significant reduction of both severity and frequency of VMS per day, resulting in an improved quality of life.","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":"19 2","pages":"69-72"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10769482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139378977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endocrine Hypertension: The Urgent Need for Greater Global Awareness. 内分泌高血压：提高全球认识的迫切需要。

TouchREVIEWS in endocrinology Pub Date : 2023-11-01 Epub Date: 2023-10-20 DOI: 10.17925/EE.2023.19.2.11

Cornelius J Fernandez, Lakshmi Nagendra, Mohammed Alkhalifah, Joseph M Pappachan

引用次数: 0